Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
This landmark recognition, fueled by the encouraging outcomes of the BIPASS-AKI feasibility study , coincides with the unveiling of pioneering research at the Society of Cardiovascular Anesthesiologists (SCA) Annual Meeting.
- This landmark recognition, fueled by the encouraging outcomes of the BIPASS-AKI feasibility study , coincides with the unveiling of pioneering research at the Society of Cardiovascular Anesthesiologists (SCA) Annual Meeting.
- The Breakthrough Device Designation emphasizes the JuxtaFlow® RAD's potential to profoundly change the treatment paradigm for patients facing kidney disease during cardiac surgery.
- John Erbey, CEO of Roivios, reflected on the significance of this achievement saying, "Securing the Breakthrough Device Designation marks a crucial milestone for Roivios and underscores our dedication to advancing kidney health innovation.
- For more information about Roivios and the JuxtaFlow® Renal Assist Device, please visit Roivios.com .